147 related articles for article (PubMed ID: 37796652)
1. Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert O; Clark SR; Fourrier C; Baune BT
J Clin Psychiatry; 2023 Oct; 84(6):. PubMed ID: 37796652
[No Abstract] [Full Text] [Related]
2. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
Baune BT; Sampson E; Louise J; Hori H; Schubert KO; Clark SR; Mills NT; Fourrier C
Eur Neuropsychopharmacol; 2021 Dec; 53():34-46. PubMed ID: 34375789
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
Fourrier C; Sampson E; Mills NT; Baune BT
Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
[TBL] [Abstract][Full Text] [Related]
4. Emotional Blunting in Depression in the PREDDICT Clinical Trial: Inflammation-Stratified Augmentation of Vortioxetine With Celecoxib.
Sampson E; Kavakbasi E; Mills NT; Hori H; Schubert KO; Fourrier C; Baune BT
Int J Neuropsychopharmacol; 2024 Mar; 27(3):. PubMed ID: 38441216
[TBL] [Abstract][Full Text] [Related]
5. Inflammation-stratified augmentation of vortioxetine with celecoxib: Results from a double-blind, randomized, placebo-controlled trial in major depressive disorder.
Kavakbasi E; Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert KO; Clark SR; Fourrier C; Baune BT
J Neurochem; 2023 Aug; ():. PubMed ID: 37635396
[TBL] [Abstract][Full Text] [Related]
6. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
Nierenberg AA; Loft H; Olsen CK
J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
[TBL] [Abstract][Full Text] [Related]
7. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
Christensen MC; Loft H; McIntyre RS
J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
[TBL] [Abstract][Full Text] [Related]
8. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls.
Smith J; Browning M; Conen S; Smallman R; Buchbjerg J; Larsen KG; Olsen CK; Christensen SR; Dawson GR; Deakin JF; Hawkins P; Morris R; Goodwin G; Harmer CJ
Mol Psychiatry; 2018 May; 23(5):1127-1133. PubMed ID: 28533517
[TBL] [Abstract][Full Text] [Related]
9. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
10. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
Vieta E; Sluth LB; Olsen CK
J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
McIntyre RS; Lophaven S; Olsen CK
Int J Neuropsychopharmacol; 2014 Oct; 17(10):1557-67. PubMed ID: 24787143
[TBL] [Abstract][Full Text] [Related]
13. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial.
Mills NT; Sampson E; Fourrier C; Baune BT
Int J Neuropsychopharmacol; 2021 Apr; 24(4):314-321. PubMed ID: 33269395
[TBL] [Abstract][Full Text] [Related]
14. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
Findling RL; DelBello MP; Zuddas A; Emslie GJ; Ettrup A; Petersen ML; Schmidt SN; Rosen M
J Am Acad Child Adolesc Psychiatry; 2022 Sep; 61(9):1106-1118.e2. PubMed ID: 35033635
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
Almeida SS; Christensen MC; Simonsen K; Adair M
J Psychopharmacol; 2023 Mar; 37(3):279-288. PubMed ID: 36377523
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
18. Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it).
Cha DS; Carmona NE; Mansur RB; Lee Y; Park HJ; Rodrigues NB; Subramaniapillai M; Rosenblat JD; Pan Z; Lee JH; Lee J; Almatham F; Alageel A; Shekotikhina M; Zhou AJ; Rong C; Harrison J; McIntyre RS
Scand J Pain; 2017 Apr; 15():62-67. PubMed ID: 28850348
[TBL] [Abstract][Full Text] [Related]
19. Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder.
Murthy NV; Xu R; Zhong W; Harvey PD
J Affect Disord; 2020 Jan; 260():550-556. PubMed ID: 31539692
[TBL] [Abstract][Full Text] [Related]
20. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.
McIntyre RS; Phan L; Kwan ATH; Mansur RB; Rosenblat JD; Guo Z; Le GH; Lui LMW; Teopiz KM; Ceban F; Lee Y; Bailey J; Ramachandra R; Di Vincenzo J; Badulescu S; Gill H; Drzadzewski P; Subramaniapillai M
Brain; 2024 Mar; 147(3):849-857. PubMed ID: 37936330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
